Eli Lilly (LLY) Cost of Revenue (2009 - 2026)
Eli Lilly posted quarterly Cost of Revenue of $3.6 billion for Q1 2026, up 60.76% year-on-year from $2.2 billion in Q1 2025, and up 6.09% on a QoQ basis from $3.4 billion in Q4 2025.
Eli Lilly (LLY) has 18 years of Cost of Revenue data on file, last reported at $3.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Cost of Revenue rose 60.76% year-over-year to $3.6 billion; the trailing twelve-month figure through Mar 2026 stood at $12.4 billion (up 38.3% YoY), and the FY2025 full-year result was $11.1 billion, up 31.29% from the prior year.
- Cost of Revenue for Q1 2026 stood at $3.6 billion, up from $3.4 billion in the prior quarter.
- Across five years, Cost of Revenue topped out at $3.6 billion in Q1 2026 and bottomed at $1.4 billion in Q2 2022.
- The 5-year median for Cost of Revenue is $2.1 billion (2022), against an average of $2.2 billion.
- The widest annual swing landed in 2022, when Cost of Revenue declined 26.76%; it then soared 60.76% in 2026.
- A 5-year view of Cost of Revenue shows it stood at $1.5 billion in 2022, then advanced by 15.48% to $1.8 billion in 2023, then jumped by 34.44% to $2.4 billion in 2024, then surged by 40.28% to $3.4 billion in 2025, then increased by 6.09% to $3.6 billion in 2026.
- The last three Cost of Revenue figures came in at $3.6 billion (Q1 2026), $3.4 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.58 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 8.11 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.22 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 4.20 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.74 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.45 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 3.55 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 3.42 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.58 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Dec 31, 2025 | 3.37 Bn |
| Dec 31, 2025 | 3.37 Bn |
| Sep 30, 2025 | 3.01 Bn |
| Sep 30, 2025 | 3.01 Bn |
| Jun 30, 2025 | 2.45 Bn |
| Jun 30, 2025 | 2.45 Bn |
| Mar 31, 2025 | 2.23 Bn |
| Mar 31, 2025 | 2.23 Bn |
| Dec 31, 2024 | 2.40 Bn |
| Dec 31, 2024 | 2.40 Bn |
| Sep 30, 2024 | 2.17 Bn |
| Sep 30, 2024 | 2.17 Bn |
| Jun 30, 2024 | 2.17 Bn |
| Jun 30, 2024 | 2.17 Bn |
| Mar 31, 2024 | 1.67 Bn |
| Mar 31, 2024 | 1.67 Bn |
| Dec 31, 2023 | 1.79 Bn |
| Dec 31, 2023 | 1.79 Bn |
| Sep 30, 2023 | 1.86 Bn |
| Sep 30, 2023 | 1.86 Bn |
| Jun 30, 2023 | 1.81 Bn |
| Jun 30, 2023 | 1.81 Bn |
| Mar 31, 2023 | 1.63 Bn |
| Mar 31, 2023 | 1.63 Bn |
| Dec 31, 2022 | 1.55 Bn |
| Dec 31, 2022 | 1.55 Bn |
| Sep 30, 2022 | 1.58 Bn |
| Sep 30, 2022 | 1.58 Bn |
| Jun 30, 2022 | 1.43 Bn |
| Jun 30, 2022 | 1.43 Bn |
| Mar 31, 2022 | 2.07 Bn |
| Mar 31, 2022 | 2.07 Bn |
| Dec 31, 2021 | 2.05 Bn |
| Dec 31, 2021 | 2.05 Bn |
| Sep 30, 2021 | 1.43 Bn |
| Sep 30, 2021 | 1.43 Bn |
| Jun 30, 2021 | 1.95 Bn |
| Jun 30, 2021 | 1.95 Bn |
| Mar 31, 2021 | 1.88 Bn |
| Mar 31, 2021 | 1.88 Bn |
| Dec 31, 2020 | 1.72 Bn |
| Dec 31, 2020 | 1.72 Bn |
| Sep 30, 2020 | 1.33 Bn |
| Sep 30, 2020 | 1.33 Bn |
| Jun 30, 2020 | 1.22 Bn |
| Jun 30, 2020 | 1.22 Bn |
| Mar 31, 2020 | 1.22 Bn |
| Mar 31, 2020 | 1.22 Bn |
| Dec 31, 2019 | 1.28 Bn |
| Dec 31, 2019 | 1.28 Bn |
| Sep 30, 2019 | 1.18 Bn |
| Sep 30, 2019 | 1.18 Bn |
| Jun 30, 2019 | 1.12 Bn |
| Jun 30, 2019 | 1.12 Bn |
| Mar 31, 2019 | 1.14 Bn |
| Mar 31, 2019 | 1.14 Bn |
| Dec 31, 2018 | 1.13 Bn |
| Dec 31, 2018 | 1.13 Bn |
| Sep 30, 2018 | 1.15 Bn |
| Sep 30, 2018 | 1.15 Bn |
| Jun 30, 2018 | 1.23 Bn |
| Jun 30, 2018 | 1.23 Bn |
| Mar 31, 2018 | 1.16 Bn |
| Mar 31, 2018 | 1.16 Bn |
| Dec 31, 2017 | 1.64 Bn |
| Dec 31, 2017 | 1.64 Bn |
| Sep 30, 2017 | 1.59 Bn |
| Sep 30, 2017 | 1.59 Bn |
| Jun 30, 2017 | 1.57 Bn |
| Jun 30, 2017 | 1.57 Bn |
| Mar 31, 2017 | 1.35 Bn |
| Mar 31, 2017 | 1.35 Bn |
| Dec 31, 2016 | 1.47 Bn |
| Dec 31, 2016 | 1.47 Bn |
| Sep 30, 2016 | 1.40 Bn |
| Sep 30, 2016 | 1.40 Bn |
| Jun 30, 2016 | 1.47 Bn |
| Jun 30, 2016 | 1.47 Bn |
| Mar 31, 2016 | 1.32 Bn |
| Mar 31, 2016 | 1.32 Bn |
| Dec 31, 2015 | 1.39 Bn |
| Dec 31, 2015 | 1.39 Bn |
| Sep 30, 2015 | 1.24 Bn |
| Sep 30, 2015 | 1.24 Bn |
| Jun 30, 2015 | 1.22 Bn |
| Jun 30, 2015 | 1.22 Bn |
| Mar 31, 2015 | 1.19 Bn |
| Mar 31, 2015 | 1.19 Bn |
| Dec 31, 2014 | 1.25 Bn |
| Dec 31, 2014 | 1.25 Bn |
| Sep 30, 2014 | 1.27 Bn |
| Sep 30, 2014 | 1.27 Bn |
| Jun 30, 2014 | 1.19 Bn |
| Jun 30, 2014 | 1.19 Bn |
| Mar 31, 2014 | 1.22 Bn |
| Mar 31, 2014 | 1.22 Bn |
| Dec 31, 2013 | 1.39 Bn |
| Dec 31, 2013 | 1.39 Bn |
| Sep 30, 2013 | 1.20 Bn |
| Sep 30, 2013 | 1.20 Bn |
| Jun 30, 2013 | 1.17 Bn |
| Jun 30, 2013 | 1.17 Bn |
| Mar 31, 2013 | 1.16 Bn |
| Mar 31, 2013 | 1.16 Bn |
| Dec 31, 2012 | 1.25 Bn |
| Dec 31, 2012 | 1.25 Bn |
| Sep 30, 2012 | 1.20 Bn |
| Sep 30, 2012 | 1.20 Bn |
| Jun 30, 2012 | 1.15 Bn |
| Jun 30, 2012 | 1.15 Bn |
| Mar 31, 2012 | 1.20 Bn |
| Mar 31, 2012 | 1.20 Bn |
| Dec 31, 2011 | 1.32 Bn |
| Dec 31, 2011 | 1.32 Bn |
| Sep 30, 2011 | 1.34 Bn |
| Sep 30, 2011 | 1.34 Bn |
| Jun 30, 2011 | 1.23 Bn |
| Jun 30, 2011 | 1.23 Bn |
| Mar 31, 2011 | 1.18 Bn |
| Mar 31, 2011 | 1.18 Bn |
| Dec 31, 2010 | 1.23 Bn |
| Dec 31, 2010 | 1.23 Bn |
| Sep 30, 2010 | 987.60 Mn |
| Sep 30, 2010 | 987.60 Mn |
| Jun 30, 2010 | 1.02 Bn |
| Jun 30, 2010 | 1.02 Bn |
| Mar 31, 2010 | 1.12 Bn |
| Mar 31, 2010 | 1.12 Bn |
| Dec 31, 2009 | 1.43 Bn |
| Dec 31, 2009 | 1.43 Bn |
| Sep 30, 2009 | 1.05 Bn |
| Sep 30, 2009 | 1.05 Bn |
| Jun 30, 2009 | 947.40 Mn |
| Jun 30, 2009 | 947.40 Mn |
| Mar 31, 2009 | 816.40 Mn |
| Mar 31, 2009 | 816.40 Mn |